JP2019533646A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533646A5
JP2019533646A5 JP2019515636A JP2019515636A JP2019533646A5 JP 2019533646 A5 JP2019533646 A5 JP 2019533646A5 JP 2019515636 A JP2019515636 A JP 2019515636A JP 2019515636 A JP2019515636 A JP 2019515636A JP 2019533646 A5 JP2019533646 A5 JP 2019533646A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533646A (ja
JP6995844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052891 external-priority patent/WO2018057849A1/en
Publication of JP2019533646A publication Critical patent/JP2019533646A/ja
Publication of JP2019533646A5 publication Critical patent/JP2019533646A5/ja
Application granted granted Critical
Publication of JP6995844B2 publication Critical patent/JP6995844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515636A 2016-09-23 2017-09-22 アトピー性皮膚炎を治療するためのil-13アンタゴニストの使用 Active JP6995844B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662398713P 2016-09-23 2016-09-23
US62/398,713 2016-09-23
US201762527204P 2017-06-30 2017-06-30
US62/527,204 2017-06-30
US201762530683P 2017-07-10 2017-07-10
US62/530,683 2017-07-10
US201762539037P 2017-07-31 2017-07-31
US62/539,037 2017-07-31
PCT/US2017/052891 WO2018057849A1 (en) 2016-09-23 2017-09-22 Uses of il-13 antagonists for treating atopic dermatitis

Publications (3)

Publication Number Publication Date
JP2019533646A JP2019533646A (ja) 2019-11-21
JP2019533646A5 true JP2019533646A5 (enExample) 2020-10-22
JP6995844B2 JP6995844B2 (ja) 2022-02-04

Family

ID=60020628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515636A Active JP6995844B2 (ja) 2016-09-23 2017-09-22 アトピー性皮膚炎を治療するためのil-13アンタゴニストの使用

Country Status (28)

Country Link
US (3) US11434286B2 (enExample)
EP (2) EP3528838B1 (enExample)
JP (1) JP6995844B2 (enExample)
KR (1) KR102557643B1 (enExample)
CN (1) CN109715201A (enExample)
AU (1) AU2017330405B2 (enExample)
CA (1) CA3031589C (enExample)
CY (2) CY1126255T1 (enExample)
DK (1) DK3528838T5 (enExample)
ES (1) ES2958593T3 (enExample)
FI (2) FI3528838T3 (enExample)
FR (1) FR24C1017I2 (enExample)
HR (1) HRP20231015T1 (enExample)
HU (2) HUE063135T2 (enExample)
IL (1) IL265473B2 (enExample)
LT (2) LT3528838T (enExample)
MX (1) MX2019002672A (enExample)
NL (1) NL301269I2 (enExample)
NZ (1) NZ790629A (enExample)
PL (1) PL3528838T3 (enExample)
PT (1) PT3528838T (enExample)
RS (1) RS64550B1 (enExample)
RU (1) RU2752785C2 (enExample)
SG (1) SG11201900845YA (enExample)
SI (1) SI3528838T1 (enExample)
TW (1) TWI787203B (enExample)
UA (1) UA124269C2 (enExample)
WO (1) WO2018057849A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CA3031589C (en) * 2016-09-23 2025-05-06 Genentech, Inc. USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
WO2021191220A1 (en) * 2020-03-23 2021-09-30 Medimmune Limited Methods for treating atopic dermatitis and related disorders
US12187788B2 (en) * 2020-03-23 2025-01-07 Medimmune Limited Methods for treating atopic dermatitis and related disorders
AU2021358274A1 (en) * 2020-10-09 2023-05-25 Kyowa Kirin Co., Ltd. Method for treating ox40 related disease
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
CA3208011A1 (en) * 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
TWI847170B (zh) * 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) * 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
IL311027A (en) * 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
IL316779A (en) * 2022-05-05 2025-01-01 Dermira Inc IL-13 antibodies for the treatment of atopic dermatitis
JP2025522482A (ja) 2022-06-17 2025-07-15 アポジー バイオロジクス, インコーポレイテッド インターロイキン13に結合する抗体及び使用方法
EP4594352A1 (en) * 2022-09-06 2025-08-06 ASLAN Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024191249A1 (ko) 2023-03-14 2024-09-19 주식회사 지오비스타 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도
KR102773781B1 (ko) 2023-03-14 2025-02-28 주식회사 지오비스타 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
KR20250017610A (ko) 2023-07-27 2025-02-04 김천균 아토피의 치료와 예방용 조성물 및 그 제조방법
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025155874A1 (en) * 2024-01-18 2025-07-24 Enveda Therapeutics, Inc. Methods and compounds for modulating immune response
WO2025264960A1 (en) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1814615B1 (en) 2004-11-24 2015-10-28 SHL Group AB Injection device
EP2526987A3 (en) 2005-06-01 2013-04-24 SHL Group AB Device for delivering medicament
DE602005008404D1 (de) 2005-06-01 2008-09-04 Shl Medical Ab Medikamentenabgabevorrichtung
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック, インコーポレイテッド Th2阻害に関連する診断及び治療
AU2013204894B2 (en) * 2010-12-16 2016-11-10 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
EP2720737B1 (en) 2011-06-17 2017-01-04 SHL Group AB Injection device
WO2012173553A1 (en) 2011-06-17 2012-12-20 Shl Group Ab Injection device
LT3091029T (lt) * 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
WO2014165771A2 (en) 2013-04-05 2014-10-09 Genentech, Inc. Anti-il-4 antibodies and bispecific antibodies and uses thereof
EP3099323A4 (en) * 2014-01-27 2017-10-04 Medlmmune, LLC Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
CA2977285A1 (en) * 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
CA3031589C (en) * 2016-09-23 2025-05-06 Genentech, Inc. USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS

Similar Documents

Publication Publication Date Title
JP2019533646A5 (enExample)
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
JP2019514974A5 (enExample)
JP2014240408A5 (enExample)
JP2016516016A5 (enExample)
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
JP2017160208A5 (enExample)
JP2022033891A (ja) 関節リウマチを治療するための組成物およびこれを使用する方法
JP2018505882A5 (enExample)
JP2017537905A5 (enExample)
JP2017534645A5 (enExample)
FI4285929T3 (fi) Hbv:n yhdistelmähoito
JP2016517421A5 (enExample)
IL310706A (en) Il-13 antibodies for the treatment of atopic dermatitis
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2017519799A5 (enExample)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
Chaplin et al. Plegridy for the treatment of RRMS in adults
IL316218A (en) Preparations and methods for treating eye diseases
NZ750179B2 (en) Uses of il-13 antagonists for treating atopic dermatitis
WO2023099668A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
JPWO2023017252A5 (enExample)
RU2024105814A (ru) Лечение атопического дерматита